Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label study designed to evaluate the safety, tolerability, PK, PD,
and preliminary efficacy of AL01211 in male subjects with classic Fabry disease who have
never received any treatment (eg. ERT or chaperone therapy). Eligible subjects will receive
182 days (26 weeks) of study treatment as the primary study period followed by an extension
period. The total study duration for a subject is up to at most 2 years including the primary
period of 26 weeks.